Abstract:AVP receptors represent a logical target for drug development. As a new class of therapeutic agents, orally active AVP analogs could be used to treat several human pathophysiological conditions including neurogenic diabetes insipidus, the syndrome of inappropriate secretion of AVP (SIADH), congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome, dysmenorrhea, and ocular hypertension. By immunoprecipitation and immunoblotting, we elucidated the phosphorylation pattern of green fluorescent protein-tagged AVP receptors and showed interactions with the specific kinases PKC and GRK5 that are agonist-, time- and receptor subtype-dependent. The tyrosine residue of the NPWIY motif present in the 7th helix of AVP receptors is rapidly and transiently phosphorylated after agonist stimulation. This phosphorylation is instrumental in the genesis of the mitogenic cascade linked to the activation of this receptor, presumably by establishing key intramolecular contacts and by participating in the creation of a scaffold of proteins that produce the activation of downstream kinases. The random screening of chemical entities and optimization of lead compounds recently resulted in the development of orally active non-peptide AVP receptor agonists and antagonists. Furthermore, the identification of the molecular determinants of receptor-ligand interactions should facilitate the development of more potent and very selective orally active compounds via the approach of structure-based drug design. We developed three-dimensional molecular docking models of peptide and non-peptide ligands to the human V1 vascular, V2 renal and V3 pituitary AVP receptors. Docking of the peptide hormone AVP to the receptor ligand binding pockets reflects its dual polar and non-polar structure, but is receptor subtype-specific. The characteristics of non-peptide AVP analogs docking to the receptors are clearly distinct from those of peptide analogs docking. Molecular modeling of the results of site-directed mutagenesis experiments performed in CHO cells stably transfected with the human AVP receptor subtypes revealed that non-peptide antagonists establish key contacts with a few amino acid residues of the receptor subtypes that are different from those involved in agonist binding. Moreover, these interactions are species-specific. These findings provide further understanding of the signal transduction pathways of AVP receptors and new leads for elucidation of drug-receptor interactions and optimization of drug design. NOTE TO THE READER: The recent cloning and molecular characterization of AVP/OT receptor subtypes call for the revision of their nomenclature. For the sake of clarity and reference to their main site of expression, we call the V1a receptor the V1 vascular receptor, the V2 receptor the V2 renal receptor and the V1b or V3 receptor the V3 pituitary receptor in the present review.

Towards understanding the role of the first extracellular loop for the binding of peptide hormones to G-protein coupled receptors

Toward a Structural Understanding of Class B GPCR Peptide Binding and Activation.

Molecular pharmacology and modeling of vasopressin receptors

Mapping the binding site of arginine vasopressin to V1a and V1b vasopressin receptors

Functional importance of two conserved residues in intracellular loop 1 and transmembrane region 2 of Family A GPCRs: Insights from ligand binding and signal transduction responses of D1 and D5 dopaminergic receptor mutants

Molecular recognition of the NPY hormone family by their receptors

Identification Of Distinct Carboxyl-Terminal Domains Mediating Internalization And Down-Regulation Of The Hamster Alpha(1b) Adrenergic Receptor

A Molecular Dynamics Study of Vasoactive Intestinal Peptide Receptor 1 and the Basis of Its Therapeutic Antagonism

Predicting the effects of amino acid replacements in peptide hormones on their binding affinities for class B GPCRs and application to the design of secretin receptor antagonists

The Structural Basis of Peptide Binding at Class A G Protein-Coupled Receptors

Linking non-peptide ligand binding mode to activity at the human cholecystokinin-2 receptor

Structural Understanding of Peptide-Bound G Protein-Coupled Receptors: Peptide-Target Interactions.

Towards Understanding the Interaction of Agonists with the Human Α1 Glycine Receptor

Molecular Basis of Class B GPCR Selectivity for the Neuropeptides PACAP and VIP

Receptor-specific recognition of NPY peptides revealed by structures of NPY receptors

Spatial Approximations Between Residues 6 and 12 in the Amino-Terminal Region of Glucagon-Like Peptide 1 and Its Receptor A Region Critical for Biological Activity

Role of lysine187 within the second extracellular loop of the type A cholecystokinin receptor in agonist-induced activation. Use of complementary charge-reversal mutagenesis to define a functionally important interdomain interaction

Structural Perspective on Ancient Neuropeptide Y-like System reveals Hallmark Features for Peptide Recognition and Receptor Activation

Deciphering specificity and cross-reactivity in tachykinin NK1 and NK2 receptors

Structural basis of ligand binding modes at the neuropeptide Y Y1 receptor

Understanding VPAC receptor family peptide binding and selectivity